Increased plasma EV levels in prostate cancer patients were reported by several studies [169,170,171,172] but reports are contradictory whether prostate cancer cell-derived EVs could be distinguished from total plasma EVs based on the presence of prostate-specific membrane antigen (PSMA) on the EV membrane. This evidence concerns the gene FOLH1 and prostate cancer.